...Spero acquired multiple antibacterial candidates from Pro Bono Bio. Spero said it will work with Pro Bono Bio’s Cantab Anti...
...of Gram-negative pathogens, such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii . Pro Bono Bio...
...to inquiries. Pro Bono Bio Group Ltd., London, U.K. Spero Therapeutics LLC , Cambridge, Mass. Business: Infectious Nora Weintraub Pro Bono Bio Group plc Spero...

...glycol molecule using PolyTherics' TheraPEG technology. Pro Bono Bio plans to start Phase I testing next year. Pro Bono Bio...
...and IX using PolyTherics' TheraPEG technology (see BioCentury, Sept. 17). PolyTherics Ltd. , London, U.K. Pro Bono Bio Group plc...

...glycol molecule using PolyTherics' TheraPEG technology. Pro Bono Bio plans to start Phase I testing next year. Pro Bono Bio...
...and IX using PolyTherics' TheraPEG technology (see BioCentury, Sept. 17). PolyTherics Ltd. , London, U.K. Pro Bono Bio Group plc...

...glycol molecule using PolyTherics' TheraPEG technology. Pro Bono Bio plans to start Phase I testing next year. Pro Bono Bio...
...and IX using PolyTherics' TheraPEG technology (see BioCentury, Sept. 17). PolyTherics Ltd. , London, U.K. Pro Bono Bio Group plc...

...to develop and commercialize a pegylated, longer-acting version of Factor VIII using PolyTherics' TheraPEG technology. Pro Bono Bio...
...for development and regulatory milestones, plus royalties on worldwide sales. Under the expanded 2009 deal, Pro Bono Bio...
...milestone payment in April for transferring its TheraPEG pegylation process for the Factor IX to Pro Bono Bio...

...milestone payment in April for transferring its TheraPEG pegylation process for the Factor IX to Pro Bono Bio...
...further development. The partners also began a feasibility study to develop a pegylated Factor VIII. Pro Bono Bio...
...worldwide rights to develop the product. Details were not disclosed. PolyTherics Ltd. , London, U.K. Pro Bono Bio Group plc...

...& Flow. Portfolio companies include oncology company Cleveland BioLabs Inc. (NASDAQ:CBLI); inflammation and dermatology company Pro Bono Bio...

...pain in the knee. The company said price will depend on the joint receiving treatment. Pro Bono Bio...
...physically sequester arachidonic acid, preventing its conversion to prostaglandin mediators involved in pain and inflammation. Pro Bono Bio...
...inflammatory skin disorders, including psoriasis and eczema, in 1Q12 and by year end 2011, respectively. Pro Bono Bio...

...its funds - about $700 million in all - into a single company. The newco, Pro Bono Bio...

...The Russian Corp. of Nanotechnologies and Celtic Pharma Holdings launched Pro Bono Bio , a newco developing products...